EpiCast Report 2016: Breast Cancer (HER2+, HER2-) - Epidemiology Forecast to 2025 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "EpiCast Report: Breast Cancer (HER2+, HER2-) - Epidemiology Forecast to 2025" drug pipelines to their offering.

The epidemiologists forecast that the diagnosed incident cases of invasive breast cancer (not including DCIS) in the 8MM for women will grow by an Annual Growth Rate (AGR) of 1.94% over the next 10 years, from 795,114 cases in 2015 to 949,161 cases in 2025. In 2015, the 60-69 year age group had the highest number of diagnosed incident cases of invasive breast cancer, contributing 195,701 (24.61%) cases of the total in the 8MM.

Uniform diagnostic criteria are used for all segmentations across the 8MM, where a breast biopsy was used to confirm cases of breast cancer. In addition, comparable staging criteria by the AJCC (American Joint Committee on Cancer) and UICC (Union for International Cancer Control) were applied across all 8MM.

Overall, the majority of diagnosed incident cases of breast cancer occurred in ages 40 years and older, accounting for 95.48% of all cases in the 8MM in 2015. The 8MM will see an increase in five-year diagnosed prevalent cases throughout the forecast period at an AGR of 2.39%, with 3,549,784 cases in 2015 and 4,399,243 in 2025. For HER2 status of diagnosed incident cases of invasive breast cancer in the 8MM throughout the forecast period, 17.53% of cases were HER2+, 68.07% were HER2-/HR+, and 14.40% were TN.

The epidemiologists utilized comprehensive, country-specific data from national breast cancer registries and peer-reviewed journal articles when available, to arrive at a meaningful, in-depth analysis and forecast for the diagnosed incident and five-year diagnosed prevalent cases of breast cancer. In this analysis, epidemiologists provide detailed, clinically relevant segmentations for diagnosed incident cases of breast cancer.

Key Topics Covered:

1 Tables & Figures

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global Trends

2.4 Forecast Methodology

2.5 Epidemiological Forecast for Non-Invasive DCIS Breast Cancer (2015-2025)

2.6 Epidemiological Forecast for Invasive Breast Cancer (2015-2025)

2.7 Discussion

3 Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/b566ln/epicast_report

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Breast Cancer Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Breast Cancer Drugs